|
1
|
Gebski V, Burmeister B, Smithers BM, Foo
K, Zalcberg J and Simes J: Australasian Gastro-Intestinal Trials
Group: Survival benefits from neoadjuvant chemoradiotherapy or
chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet
Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blum MA, Taketa T, Sudo K, Wadhwa R,
Skinner HD and Ajani JA: Chemoradiation for esophageal cancer.
Thorac Surg Clin. 23:551–558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blom RL, Steenbakkers IR, Lammering G,
Vliegen RF, Belgers EJ, de Jonge C, Schreurs WM, Nap M and Sosef
MN: PET/CT-based metabolic tumour volume for response prediction of
neoadjuvant chemoradiotherapy in oesophageal carcinoma. Eur J Nucl
Med Mol Imaging. 40:1500–1506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hulshoff JB, Smit JK, van der Jagt EJ and
Plukker JT: Evaluation of progression prior to surgery after
neoadjuvant chemoradiotherapy with computed tomography in
esophageal cancer patients. Am J Surg. 280:73–79. 2014. View Article : Google Scholar
|
|
5
|
Krasna MJ: Radiographic and
endosonographic staging in esophageal cancer. Thorac Surg Clin.
23:453–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lutz MP, Zalcberg JR, Ducreux M, Ajani JA,
Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, et
al: Highlights of the EORTC St. Gallen International Expert
Consensus on the primary therapy of gastric, gastroesophageal and
oesophageal cancer-differential treatment strategies for subtypes
of early gastroesophageal cancer. Eur J Cancer. 48:2941–2953. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi W, Wang W, Wang J, Cheng H and Huo X:
Meta-analysis of 18FDG PET-CT for nodal staging in patients with
esophageal cancer. Surg Oncol. 22:112–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marzola MC, De Manzoni G, Grassetto G,
Cordiano C, Al-Nahhas A, Alavi A and Rubello D: Extended staging of
oesophageal cancer using FDG-PET - a critical appraisal. Eur J
Radiol. 81:21–30. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mantovani A, Marchesi F, Portal C,
Allavena P and Sica A: Linking inflammation reactions to cancer:
Novel targets for therapeutic strategies. Adv Exp Med Biol.
610:112–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantovani A: Molecular pathways linking
inflammation and cancer. Curr Mol Med. 10:369–373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aldinucci D and Colombatti A: The
inflammatory chemokine CCL5 and cancer progression. Mediators
Inflamm. 2014:2923762014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ham M and Moon A: Inflammatory and
microenvironmental factors involved in breast cancer progression.
Arch Pharm Res. 36:1419–1431. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim ES, Cha Y, Ham M, Jung J, Kim SG,
Hwang S, Kleemann R and Moon A: Inflammatory lipid
sphingosine-1-phosphate upregulates C-reactive protein via C/EBPβ
and potentiates breast cancer progression. Oncogene. 33:3583–3593.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mantovani A and Pierotti MA: Cancer and
inflammation: A complex relationship. Cancer Lett. 267:180–181.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morrison WB: Inflammation and cancer: A
comparative view. J Vet Intern Med. 26:18–31. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lukaszewicz-Zając M, Mroczko B, Kozłowski
M, Nikliński J, Laudański J, Siewko M and Szmitkowski M:
Comparative evaluation of serum C-reactive protein (CRP) levels in
the different histological subtypes of esophageal cancer (squamous
cell carcinoma and adenocarcinoma of esophagus). J Clin Lab Anal.
26:73–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watanabe T, Shibata M, Nishiyama H, Soeda
S, Furukawa S, Gonda K, Takenoshita S and Fujimori K: Serum levels
of rapid turnover proteins are decreased and related to systemic
inflammation in patients with ovarian cancer. Oncol Lett.
7:373–377. 2014.PubMed/NCBI
|
|
20
|
Swede H, Hajduk AM, Sharma J, Rawal S,
Rasool H, Vella AT, Tobet RE and Stevens RG: Baseline serum
C-reactive protein and death from colorectal cancer in the NHANES
III cohort. Int J Cancer. 134:1862–1870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu M, Zhu M, Du Y, Yan B, Wang Q, Wang C
and Zhao J: Serum C-reactive protein and risk of lung cancer: A
case-control study. Med Oncol. 30:3192013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tibau A, Ennis M and Goodwin PJ:
Post-surgical highly sensitive C-reactive protein and prognosis in
early-stage breast cancer. Breast Cancer Res Treat. 141:485–493.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McMillan DC: The systemic
inflammation-based Glasgow Prognostic Score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laird BJ, Kaasa S, McMillan DC, Fallon MT,
Hjermstad MJ, Fayers P and Klepstad P: Prognostic factors in
patients with advanced cancer: A comparison of clinicopathological
factors and the development of an inflammation-based prognostic
system. Clin Cancer Res. 19:5456–5464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kersten C, Louhimo J, Algars A, Lahdesmaki
A, Cvancerova M, Stenstedt K, Haglund C and Gunnarsson U: Increased
C-reactive protein implies a poorer stage-specific prognosis in
colon cancer. Acta Oncol. 52:1691–1698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mohri Y, Tanaka K, Ohi M, Toiyama Y,
Yasuda H, Inoue Y, Uchida K and Kusunoki M: Inflammation-based
prognostic score as a predictor of postoperative gastric cancer
recurrence. Anticancer Res. 32:4581–4584. 2012.PubMed/NCBI
|
|
27
|
Jiang X, Hiki N, Nunobe S, Kumagai K,
Kubota T, Aikou S, Sano T and Yamaguchi T: Prognostic importance of
the inflammation-based Glasgow prognostic score in patients with
gastric cancer. Br J Cancer. 107:275–279. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX,
Chen YJ and Xu Q: Prognostic role of C-reactive protein in prostate
cancer: A systematic review and meta-analysis. Asian J Androl.
16:467–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu Q, Yu XF, Zhang SD, Wang HH, Wang HY
and Teng LS: Prognostic role of C-reactive protein in gastric
cancer: A meta-analysis. Asian Pac J Cancer Prev. 14:5735–5740.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo YZ, Pan L, Du CJ, Ren DQ and Xie XM:
Association between C-reactive protein and risk of cancer: A
meta-analysis of prospective cohort studies. Asian Pac J Cancer
Prev. 14:243–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou B, Liu J, Wang ZM and Xi T:
C-reactive protein, interleukin 6 and lung cancer risk: A
meta-analysis. PLoS One. 7:e430752012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qayyum T, McArdle PA, Lamb GW, Going JJ,
Orange C, Seywright M, Horgan PG, Oades G, Aitchison MA and Edwards
J: Prospective study of the role of inflammation in renal cancer.
Urol Int. 88:277–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S,
Zhang W, Sun Q and Zhao Y: Prognostic role of C-reactive protein in
breast cancer: A systematic review and meta-analysis. Int J Biol
Markers. 26:209–215. 2011.PubMed/NCBI
|
|
34
|
Heikkilä K, Harris R, Lowe G, Rumley A,
Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S and Lawlor DA:
Associations of circulating C-reactive protein and interleukin-6
with cancer risk: Findings from two prospective cohorts and a
meta-analysis. Cancer Causes Control. 20:15–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guillem P and Triboulet JP: Elevated serum
levels of C-reactive protein are indicative of a poor prognosis in
patients with esophageal cancer. Dis Esophagus. 18:146–150. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Crumley AB, McMillan DC, McKernan M, Going
JJ, Shearer CJ and Stuart RC: An elevated C-reactive protein
concentration, prior to surgery, predicts poor cancer-specific
survival in patients undergoing resection for gastro-oesophageal
cancer. Br J Cancer. 94:1568–1571. 2006.PubMed/NCBI
|
|
37
|
Crumley AB, Stuart RC, McKernan M,
McDonald AC and McMillan DC: Comparison of an inflammation-based
prognostic score (GPS) with performance status (ECOG-ps) in
patients receiving palliative chemotherapy for gastroesophageal
cancer. J Gastroenterol Hepatol. 23:e325–e329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Motoyama S, Miura M, Hinai Y, Maruyama K,
Usami S, Nakatsu T, Saito H, Minamiya Y, Suzuki T and Ogawa J:
C-reactive protein 1059G>C genetic polymorphism influences serum
C-reactive protein levels after esophagectomy in patients with
thoracic esophageal cancer. J Am Coll Surg. 209:477–483. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shimada H, Nabeya Y, Okazumi S, Matsubara
H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S
and Ochiai T: Elevation of preoperative serum C-reactive protein
level is related to poor prognosis in esophageal squamous cell
carcinoma. J Surg Oncol. 83:248–252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang
HW, Fang FM and Huang YJ: Higher serum C-reactive protein
concentration and hypoalbuminemia are poor prognostic indicators in
patients with esophageal cancer undergoing radiotherapy. Radiother
Oncol. 92:270–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Groblewska M, Mroczko B, Sosnowska D and
Szmitkowski M: Interleukin 6 and C-reactive protein in esophageal
cancer. Clin Chim Acta. 413:1583–1590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Miyata H, Yamasaki M, Kurokawa Y,
Takiguchi S, Nakajima K, Fujiwara Y, Mori M and Doki Y: Prognostic
value of an inflammation-based score in patients undergoing
pre-operative chemotherapy followed by surgery for esophageal
cancer. Exp Ther Med. 2:879–885. 2011.PubMed/NCBI
|
|
43
|
Zingg U, Forberger J, Rajcic B, Langton C
and Jamieson GG: Association of C-reactive protein levels and
long-term survival after neoadjuvant therapy and esophagectomy for
esophageal cancer. J Gastrointest Surg. 14:462–469. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM: Classification of Malignant Tumours (7th). Hoboken, NJ:
Wiley-Blackwell. 2009.
|
